NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing nanomedicines for antiviral therapy, announced it will present at the NIBA 153rd Investment Conference on October 7, 2026, in Fort Lauderdale, Florida. The presentation comes as the company advances its lead drug candidate, NV-387, a broad-spectrum antiviral currently in separate Phase 2 clinical trials in the Democratic Republic of Congo for Ebola Bundibugyo virus disease and Mpox. The company is also planning clinical trials of NV-387 for measles, for which the drug has received Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration, as well as for viral acute respiratory infections.
The significance of NanoViricides’ work lies in its potential to address multiple high-consequence viral diseases with a single platform technology. The nanoviricide class of drug candidates is designed to mimic the host cell’s attachment site to attract and neutralize viruses, a mechanism that could overcome the challenge of viral mutation. If successful, NV-387 could provide a broad-spectrum defense against a range of pathogens, from Ebola and Mpox to measles and respiratory viruses, filling critical gaps in global preparedness. The company’s pipeline also includes NV-HHV-1 for herpesviridae viruses and NV-HIV-1 for HIV/AIDS, further underscoring its ambition to tackle diverse viral threats. For investors, the NIBA conference offers an opportunity to gauge the company’s progress as it navigates the lengthy and capital-intensive drug development process. As noted in the press release, there can be no assurance that any of the company’s pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development. However, the ongoing Phase 2 trials and FDA designations provide tangible validation of the platform’s potential. The measles program, in particular, could benefit from the Rare Pediatric Disease Designation, which may entitle NanoViricides to a priority review voucher upon approval, a valuable asset. The company’s business model relies on licensing technology from TheraCour Pharma, Inc., and it holds worldwide exclusive licenses for several viral diseases. More information about NanoViricides is available at www.nanoviricides.com, and the full press release can be viewed at https://ibn.fm/vQCM4. The latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC. The announcement was distributed by InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio @ IBN. InvestorWire provides access to a vast network of wire solutions, including editorial syndication to 5,000+ outlets and social media distribution, as well as a full array of tailored corporate communications solutions. For full terms of use and disclaimers, visit https://www.InvestorWire.com/Disclaimer.
